You are here

Article Text

Article menu
Download PDFPDF
CASE REPORT
Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant
  1. Mortimer B O'Connor1,2,
  2. Neil O'Donovan3,
  3. Ursula Bond2,
  4. Mark J Phelan1,2
  1. 1Department of Medicine, Mercy University Hospital, Cork, Ireland
  2. 2Department of Rheumatology, South Infirmary Victoria University Hospital, Cork, Ireland
  3. 3Department of Radiology, South Infirmary Victoria University Hospital, Cork, Ireland
  1. Correspondence to Dr Mortimer B O'Connor, mortimeroconnor{at}gmail.com

Summary

Takayasu arteritis is a rare large vessel vasculitis which has traditionally been treated with high-dose steroids. There have been a small number of publications where biological agents have been used to manage refractory cases. To the authors knowledge, there are no publications using biological agents in combination with steroids as a first-line treatment in Takayasu arteritis. In this publication, we document the case of Takayasu arteritis, in a 39-year-old woman, where rituximab was used in combination with steroids as a first-line agent in the setting of poorly controlled bipolar affective disorder.

https://doi.org/10.1136/bcr-2016-217313

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors MBO and MJP interviewed and examined the patient, actively involved in patient care, carried out the review of patient records and result and prepared the manuscript. NO carried out the review of patient radiology and prepared the manuscript. UB interviewed and examined the patient, actively involved in patient care and prepared the manuscript.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.